DelveInsight’s, “Dengue Fever Pipeline Insight 2023,” report provides comprehensive insights about 10+ companies and 10+ pipeline drugs in the Dengue Fever pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.
For Dengue Fever Emerging drugs, the Dengue Fever pipeline analysis report provides a 360° view of the therapeutics landscape by development point, product type, route of administration, molecule type, and MOA. The Dengue Fever pipeline research covers business opportunities, challenges, future partnerships, strong competitors, and growth strategies.
In the Dengue Fever Pipeline Report, a detailed description of the drug is given which includes the mechanism of action of the drug, Dengue Fever clinical trials studies, Dengue Fever NDA approvals (if any), and product development activities comprising the technology, Dengue Fever collaborations, licensing, mergers and acquisition, funding, designations, and other product-related details.
Key takeaways from the Dengue Fever Pipeline Report
Request a sample and discover the recent breakthroughs happening in the Dengue Fever Pipeline landscape @ Dengue Fever Pipeline Outlook Report
Dengue Fever Overview
Dengue Virus (DENV) is an arbovirus (arthropod-borne virus). Four serotypes of DENV are responsible for the infectious disease called dengue that annually affects nearly 400 million people worldwide. Dengue fever is a common mosquito-borne illness in many tropical and subtropical countries. Classic dengue fever, or “break bone fever,” is characterized by acute onset of high fever 3–14 days after the bite of an infected mosquito.
Recent Developmental Activities in the Dengue Fever Treatment Landscape
For further information, refer to the detailed Dengue Fever Drugs Launch, Dengue Fever Developmental Activities, and Dengue Fever News, click here for Dengue Fever Ongoing Clinical Trial Analysis
Dengue Fever Emerging Drugs Profile
Takeda’s TAK-003 is an investigational live-attenuated tetravalent dengue vaccine, preventing dengue fever caused by any of the four serotypes of the dengue virus of which can cause dengue fever or Severe Dengue. Takeda’s current clinical development program consists of five Phase 3 trials of TAK003 Clinical Phase 1 and 2 data in children and adolescents showed that TAK-003 induced immune responses against all four dengue serotypes.
Merck & Co’s adjuvanted, tetravalent subunit vaccine V180 comprises truncated forms of envelope proteins (DEN-80E), derived from strains of all four dengue virus serotypes. The DEN-80E subunits are expressed from plasmids in the Drosophila S2 cell expression system and are formulated with either ISCOMATRIX and Alhydrogel.V180’s more compact dosing schedule could make it a more attractive alternative to Dengvaxia, particularly for travelers. However, its current three-dose schedule could still be improved to reduce the risk of non-compliance. It is believed that V180 would achieve its greatest commercial potential as part of a heterologous prime-boost strategy with TetraVax-DV. V180 is currently in Phase I development .
AV-1 is a human monoclonal antibody (mAb) being investigated as a potential therapy for dengue, a mosquito-borne viral disease with extensive global public health impact. Currently Av1 is being studied in phase I in adult healthy individuals.
Dengue Fever Pipeline Therapeutics Assessment
There are approx. 10+ key companies which are developing the therapies for Dengue Fever. The companies which have their Dengue Fever drug candidates in the mid to advanced stage, i.e. phase III and Phase II include, Takeda and others.
Find out more about the Dengue Fever Pipeline Segmentation, Therapeutics Assessment, and Dengue Fever Emerging Drugs @ Dengue Fever Treatment Landscape
Scope of the Dengue Fever Pipeline Report
Dive deep into rich insights for drugs for Dengue Fever Pipeline Companies and Therapies, click here @ Dengue Fever Unmet Needs and Analyst Views
Table of Content
Got Queries? Find out the related information on Dengue Fever Mergers and acquisitions, Dengue Fever Licensing Activities @ Dengue Fever Emerging Drugs, and Recent Trends
About Us
DelveInsight is a Business Consulting and Market research company, providing expert business solutions for the healthcare domain and offering quintessential advisory services in the areas of R&D, Strategy Formulation, Operations, Competitive Intelligence, Competitive Landscaping, and Mergers & Acquisitions.
Media ContactCompany Name: DelveInsightContact Person: Yash BhardwajEmail: Send EmailPhone: +91 9568243403Address:304 S. Jones Blvd #2432City: Las VegasState: NVCountry: United StatesWebsite: https://www.delveinsight.com/